Takeda Pharmaceutical (TAK) Interest & Investment Income (2017 - 2026)

Takeda Pharmaceutical's Interest & Investment Income history runs 10 years deep, the most recent figure standing at $32.9 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 93.21% year-over-year to $32.9 million in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 67.07% increase from a year earlier, with the FY2026 full-year figure at $1.4 billion, up 359.08% from the prior year.
• Interest & Investment Income declined to $32.9 million in Q1 2026 per TAK's latest filing, from $121.5 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $1.4 billion in Q3 2025 and bottomed at -$165.6 million in Q1 2022.
• The 5-year median for Interest & Investment Income is $207.2 million (2024), against an average of $295.1 million.
• Biggest YoY gain for Interest & Investment Income was 709.05% in 2022; the steepest drop was 136.92% in 2022.
• Year by year, Interest & Investment Income stood at $295.0 million in 2022, then tumbled by 67.9% to $94.7 million in 2023, then rose by 29.87% to $123.0 million in 2024, then decreased by 1.21% to $121.5 million in 2025, then slumped by 72.96% to $32.9 million in 2026.
• Per Business Quant, the three latest TAK Interest & Investment Income figures stand at $32.9 million (Q1 2026), $121.5 million (Q4 2025), and $1.4 billion (Q3 2025).